Catalent signs agreement for first-in-class oncological therapy

Zumutor Biologics has chosen Catalent to provide process optimisation and drug substance manufacturing services

picture of

Breaking News

Horizon Discovery expands cell-based CRISPR screening services

Cell line engineering specialist has expanded its range to complement its T cell screening service ­

AstraZeneca joins forces with Silence to develop siRNA therapeutics

Collaboration with Silence Therapeutics has been agreed to develop small interfering RNA therapeutics that act inside ...

Dover acquires equipment supplier to expand biopharma presence

Dover has agreed to acquire flow measurement device manufacturer Em-tec and will integrate into its Pumps & Process ...

New technology in cell and gene therapies to meet patient needs

Angela Myers, Head of Gene Editing and Novel Modalities at Merck, outlines the challenges arising with the increasing ...

High-throughput technologies: a paradigm shift in biopharmaceutical development

The growing demand for innovative biopharmaceutical products is putting pressure on the pharmaceutical biotechnology ...

Tepnel Pharma Services takes first step towards employee ownership

The QC company's transition to employee-ownership has been set in motion to generate a reciprocal culture that is on ...

Medical cannabis made in Italy

Dr Fabio Di Francesco, a compounding pharmacist based in Rome, describes how cannabis is used in various dosage forms ...

WuXi completes weather-tight seal of Irish biologics facility

WuXi Biologics has completed the seal of its first global supply facility in Europe that began construction in February ...

FDA releases final guidance for upcoming biological product transition

The BPCI Act requires that a marketing application for a “biological product” must be submitted as a biologics ...

Supply and demand trends in the mammalian biomanufacturing industry

BDO-USA's Dawn M. Ecker, Director, bioTRAK Database Services, and Patricia Seymour, Managing Director, BioProcess ...

Future market dynamics and opportunities in immuno-oncology

Long-term survival, tumour-agnostic effects and the potential for cure in a fraction of patients are key catalysts ...

Better by design: the role of delivery device in biosimilar adoption

George I’ons of Owen Mumford Pharmaceutical Services analyses the uptake of new biosimilars and their advancing ...

Domain makes two acquisitions for G Protein-Coupled Receptor programme

Prestwick Chemical and Neurofit are former subsidiaries of Australia-based Bionomics

Bioprocess expert chooses PM Group to design training facility expansion

National Institute for Bioprocessing Research has chosen PM Group to develop a design to expand its existing facility ...